Compare Mondaycom Ltd (MNDY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Neurocrine Biosciences Inc — how do they compare? Mondaycom Ltd trades at $88.5 (market cap $3.76B), while Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.8× Mondaycom Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| MNDY | NBIX | |
|---|---|---|
Market Cap | $3.76B | $14.36B |
Volume | 836,200 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $205.24 | $185.50 |
52-Week Low | $58.81 | $123.10 |
Typical Hold Time | 16 Days | — |
Enterprise Value | $2.92B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) is trading at $89.50, up 7.17% with strong momentum following consecutive earnings beats. The stock shows bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company maintains robust revenue growth ($1.23B in 2025) and high gross margins (88.74%), though valuation multiples remain elevated with P/E at 37.69. Recent news highlights strong enterprise client growth and AI integration initiatives at the upcoming Elevate '26 conference.
The outlook remains positive with 65% analyst buy ratings and a $108.64 consensus target, representing 21% upside. Key risks include competitive pressure from Meta's enterprise push and elevated valuation sensitivity. Earnings momentum and enterprise expansion provide catalysts, but investors should monitor Q3 2026 results against the $1.37 EPS expectation for sustained growth validation.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
